Special drug use surveillance of Leuplin PRO for Injection Kit 22.5 mg in "Premenopausal breast cancer"
Latest Information Update: 07 Jan 2022
At a glance
- Drugs Leuprorelin (Primary)
- Indications Breast cancer
- Focus Adverse reactions
- Sponsors Takeda
- 06 Sep 2018 Status changed from active, no longer recruiting to completed.
- 05 Mar 2018 Status changed from recruiting to active, no longer recruiting.
- 18 Jun 2016 New trial record